Affordable Access

deepdyve-link
Publisher Website

Effect of Sarcopenia and Body Shape on Cardiovascular Disease According to Obesity Phenotypes.

Authors
  • Cho, Hyun-Woong1
  • Chung, Wankyo2, 3
  • Moon, Shinje1
  • Ryu, Ohk-Hyun1
  • Kim, Min Kyung1
  • Kang, Jun Goo1
  • 1 Division of Endocrinology and Metabolism, Hallym University College of Medicine, Chuncheon, Korea. , (North Korea)
  • 2 Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, Korea. , (North Korea)
  • 3 Institute of Health and Environment, Seoul National University, Seoul, Korea. , (North Korea)
Type
Published Article
Journal
Diabetes & metabolism journal
Publication Date
Mar 01, 2021
Volume
45
Issue
2
Pages
209–218
Identifiers
DOI: 10.4093/dmj.2019.0223
PMID: 32662256
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

This study aimed to assess the effects of sarcopenia and A Body Shape Index (ABSI) on cardiovascular disease (CVD) risk according to obesity phenotypes. We used data from the National Health and Nutrition Examination Survey 1999 to 2012. A total of 25,270 adults were included and classified into the following groups: metabolically healthy normal weight (MHNW), metabolically healthy overweight/obese (MHO), metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese (MUO). Sarcopenia was defined as the appendicular skeletal mass index <7 kg/m2 in men and <5.5kg/m2 in women. A multivariate logistic regression analysis was performed to evaluate the odds ratio (OR) of sarcopenia and ABSI for CVD events according to the obesity phenotype. The MHNW participants with sarcopenia had higher risk for CVD than those without sarcopenia (OR, 2.69; 95% confidence interval [CI], 1.56 to 4.64). In the analysis with MHNW participants without sarcopenia as a reference, the participants with sarcopenia showed a higher OR for CVD than those without sarcopenia in both MHO (OR in participants without sarcopenia, 3.31; 95% CI, 1.94 to 5.64) (OR in participants with sarcopenia, 8.59; 95% CI, 2.63 to 28.04) and MUO participants (OR in participants without sarcopenia, 5.11; 95% CI, 3.21 to 8.15) (OR in participants with sarcopenia, 8.12; 95% CI, 4.04 to 16.32). Participants within the second and third tertiles of ABSI had higher ORs for CVDs than the counterpart of obesity phenotypes within the first tertile. These results suggest that clinical approaches that consider muscle and body shape are required.

Report this publication

Statistics

Seen <100 times